Dianthus Therapeutics, Inc. /DE/

DNTH

Dianthus Therapeutics, Inc. /DE/

DNTH

Insider Sentiment (TTM):

Last Purchase:2023-09-29Last Sale:2026-06-17Shares Purchased (TTM):0Shares Sold (TTM):557,374

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:59,287,735Shares Outstanding:48,032,742Institutional Ownership Pct.:123.43%

Earnings Market Reaction:

Filing Date:2026-08-04Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	111	628	51	56	13	10	23	34	314	330	132	157
Short Term Investments	776	484	353	347	244	253	252	247	47	47	41	33
Other Receivables Net Current	-	-	0	0	0	0	1	-	-	-	-	-
Accounts Receivable Net Current	0	1	0	5	0	1	0	1	1	0	0	0
Unbilled Receivables Current	-	-	-	-	-	-	-	-	-	-	-	1
Prepaid Expense And Other Assets Current	11	7	5	6	6	7	5	4	3	3	3	1
Assets Current	898	1,120	409	414	264	271	281	287	366	381	177	191
Long Term Investments	304	114	110	153	52	68	82	61	-	-	0	-
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	1	1	1	1	1	1	2	0	0	1	1	1
Assets	1,213	1,247	531	577	326	349	374	354	369	382	179	192
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	6	5	10	7	5	8	5	8	4	3	3	1
Accrued Liabilities Current	26	31	19	16	14	8	13	8	6	6	7	11
Deferred Revenue Current	2	1	1	1	0	0	0	0	0	0	0	0
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current	34	38	31	24	20	17	18	16	10	9	10	13
Deferred Revenue Noncurrent	6	6	6	6	2	2	2	1	1	1	0	1
Operating Lease Liability Noncurrent	1	1	1	1	1	1	1	0	0	0	0	0
Temporary Equity Carrying Amount Attributable To P…	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities	41	46	38	31	23	20	22	16	11	10	11	14
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,602	1,579	830	819	538	532	527	483	479	476	258	257
Retained Earnings Accumulated Deficit	-428	-378	-337	-272	-236	-204	-174	-146	-121	-103	-89	-79
Accumulated Other Comprehensive Income Loss Net Of…	-2	-1	0	0	0	0	0	1	-0	-0	0	-0
Temporary Equity Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	-	0	0
Stockholders Equity	1,172	1,201	493	546	303	329	352	338	358	373	169	178
Liabilities And Stockholders Equity	1,213	1,247	531	577	326	349	374	354	369	382	179	192
Temporary Equity Shares Authorized	-	-	-	-	-	-	-	-	-	-	0	0
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Temporary Equity Shares Issued	-	-	-	-	-	-	-	-	-	-	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Temporary Equity Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0	0
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity Liquidation Preference	-	-	-	-	-	-	-	-	-	-	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	55	55	43	43	32	32	31	29	29	29	15	11
Shares Outstanding	55	55	43	43	32	32	31	29	29	29	15	15

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	3.07%	5.66%	15.10%	-	-	-	-	-	-	-	-	-
2025	-6.13%	-6.13%	2.54%	23.08%	91.70%	71.91%	30.39%	24.01%	55.14%	8.54%	10.34%	17.39%
2024	-13.32%	3.81%	16.21%	7.82%	1.87%	3.63%	-19.77%	-23.95%	-29.06%	-31.05%	-7.19%	-25.62%
2023	-	-	-	-	-	-	-1.23%	-8.85%	56.70%	-7.34%	-13.06%	-27.95%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	26.10	29.25	13.32	17.35	13.12	15.99	15.22	18.30	36.46	42.52	18.42	14.64
Quick Ratio	25.79	29.06	13.16	17.09	12.81	15.59	14.96	18.07	36.13	42.18	18.09	14.57
Working Capital	863.15M	1.08B	378.71M	389.97M	243.51M	254.05M	262.45M	271.78M	355.66M	371.97M	167.82M	178.37M
Leverage & Debt
Debt to Equity	0.04	0.04	0.08	0.06	0.08	0.06	0.06	0.05	0.03	0.03	0.06	0.08
Debt Ratio	0.03	0.04	0.07	0.05	0.07	0.06	0.06	0.05	0.03	0.03	0.06	0.07
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.01	0.01	0.02	0.02	0.02	0.02	0.01	0.02	0.04
Days Sales Outstanding TTM	23.15	304.62	9.32	378.87	33.05	40.14	-	55.16	74.45	49.25	322.51	11.12
Receivables Turnover TTM	15.77	1.20	39.15	0.96	11.04	9.09	-	6.62	4.90	7.41	1.13	32.81
Per Share Metrics
Diluted EPS TTM	-3.43	-3.62	-4.20	-3.34	-3.20	-2.81	-2.55	-1.96	-1.66	-1.96	-8.45	-3.45
Free Cash Flow Per Share TTM	-2.76	-2.72	-3.35	-2.17	-2.03	-2.54	-2.35	-1.83	-1.50	-1.62	-7.22	-8.76
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-19,058.97%	-14,318.04%	-8,739.34%	-4,558.41%	-2,676.56%	-1,796.40%	-1,633.74%	-1,544.99%	-1,669.82%	-1,809.40%	-1,704.67%	-193.77%
Net Profit Margin TTM	-16,819.42%	-12,998.50%	-7,973.33%	-4,104.78%	-2,364.11%	-1,544.02%	-1,362.77%	-1,250.32%	-1,376.42%	-1,557.51%	-1,541.22%	-176.84%
Growth Metrics
Net Revenue Growth (1Y)	-76.45%	-79.52%	-67.35%	-42.64%	17.87%	102.36%	120.63%	-29.52%	-47.62%	-53.23%	-55.96%	549.02%
Net Income Growth (1Y)	67.53%	72.40%	91.05%	88.32%	102.46%	100.61%	95.08%	398.34%	774.17%	298.05%	52.95%	-79.99%
EPS Growth (1Y)	7.11%	28.46%	64.82%	70.59%	93.44%	43.85%	-69.82%	-43.13%	-77.65%	-86.43%	-74.05%	-95.52%
Valuation Metrics
P/E TTM	-28.41	-23.21	-9.80	-11.77	-5.82	-6.45	-8.55	-13.97	-15.63	-15.33	-1.23	-3.97
P/B TTM	4.66	3.36	3.23	2.72	2.20	1.98	2.06	2.77	2.47	2.07	0.32	0.30
P/S TTM	4,778.41	3,017.15	781.65	483.17	137.49	99.52	116.48	174.69	215.10	238.82	18.97	7.02
Market Cap	5.46B	4.03B	1.59B	1.49B	667.37M	649.24M	726.24M	937.40M	885.80M	769.96M	53.60M	53.41M
Enterprise Value	5.35B	3.40B	1.54B	1.43B	654.13M	639.13M	703.45M	903.50M	571.63M	440.17M	-78.73M	-103.87M
Calculated Values
Free Cash Flow TTM	-154.50M	-130.49M	-129.27M	-81.97M	-72.71M	-90.97M	-78.29M	-62.67M	-51.44M	-41.65M	-37.20M	-34.22M
Net Debt	-110.72M	-627.84M	-51.25M	-55.98M	-13.24M	-10.12M	-22.79M	-33.90M	-314.17M	-329.79M	-132.33M	-157.28M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-17Sale

Owner: Veness, Adam M

Title: SVP, General Counsel and Sec.

Shares: 30,000

Price/Share: $80.86

Value: $2,425,800.00

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-06-01Sale

Owner: Randhawa, Simrat

Title: EVP, Head of R&D

Shares: 26,530

Price/Share: $90.60

Value: $2,403,618.00

Shares Owned: 4,000

Relationship: Officer

Ownership: Direct

2026-05-08Sale

Owner: Soteropoulos, Paula

Title: -

Shares: 599

Price/Share: $85.47

Value: $51,196.53

Shares Owned: -

Relationship: Director

Ownership: Direct

2026-04-09Sale

Owner: Savitz, Ryan

Title: EVP, CFO & CBO

Shares: 8,224

Price/Share: $89.84

Value: $738,844.16

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-03-31Sale

Owner: Soteropoulos, Paula

Title: -

Shares: 599

Price/Share: $80.11

Value: $47,985.89

Shares Owned: -

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-17	Veness, Adam M	Officer	SVP, General Counsel and Sec.	Direct	Sale	30,000	80.86	$2,425,800.00	0	4
2026-06-01	Randhawa, Simrat	Officer	EVP, Head of R&D	Direct	Sale	26,530	90.60	$2,403,618.00	4,000	4
2026-05-08	Soteropoulos, Paula	Director	-	Direct	Sale	599	85.47	$51,196.53	0	4
2026-04-09	Savitz, Ryan	Officer	EVP, CFO & CBO	Direct	Sale	8,224	89.84	$738,844.16	0	4
2026-03-31	Soteropoulos, Paula	Director	-	Direct	Sale	599	80.11	$47,985.89	0	4
2026-03-31	Savitz, Ryan	Officer	EVP, CFO & CBO	Direct	Sale	114,367	81.96	$9,373,519.32	0	4
2026-03-24	Soteropoulos, Paula	Director	-	Direct	Sale	27,594	78.05	$2,153,711.70	0	4
2026-03-12	Randhawa, Simrat	Officer	EVP, Head of R&D	Direct	Sale	33,830	81.48	$2,756,468.40	0	4
2026-03-12	Carr, Edward	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	43,682	82.81	$3,617,306.42	0	4
2026-03-12	Garcia, Marino	Director,Officer	CEO AND PRESIDENT	Direct	Sale	122,918	82.79	$10,176,381.22	0	4
2025-12-04	Savitz, Ryan	Officer	CFO & CBO	Direct	Sale	20,000	45.18	$903,600.00	0	4
2025-11-14	Randhawa, Simrat	Officer	EVP, Head of R&D	Direct	Sale	109,031	38.14	$4,158,442.34	4,000	4
2025-09-09	Savitz, Ryan	Officer	CFO & CBO	Direct	Sale	20,000	35.00	$700,000.00	0	4
2023-09-29	Harwin, Peter Evan, Kisel…	Director,TenPercentOwner	-	Indirect	Purchase	24,670	13.63	$336,252.10	1,928,503	4
2023-09-26	Kiselak, Tomas, Fairmount…	Director,TenPercentOwner	-	Indirect	Purchase	30,000	13.15	$394,500.00	1,903,833	4
2023-09-22	Randhawa, Simrat	Officer	Chief Medical Officer	Direct	Purchase	2,000	13.20	$26,400.00	4,000	4
2023-09-19	Kiselak, Tomas, Harwin Pe…	Director,TenPercentOwner	-	Indirect	Purchase	30,000	13.20	$396,000.00	1,873,833	4
2023-09-13	Kiselak, Tomas, Fairmount…	Director,TenPercentOwner	-	Indirect	Purchase	9,367	11.76	$110,155.92	1,843,833	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

123.43%

Inst. Shares: 59,287,735

Shares Outstanding: 48,032,742

2025-12-31

125.15%

Inst. Shares: 48,329,472

Shares Outstanding: 38,617,580

2025-09-30

123.29%

Inst. Shares: 46,596,484

Shares Outstanding: 37,794,088

2025-06-30

108.69%

Inst. Shares: 38,936,319

Shares Outstanding: 35,822,308

2025-03-31

98.60%

Inst. Shares: 35,287,915

Shares Outstanding: 35,790,700

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	59,287,735	48,032,742	123.43%
2025-12-31	48,329,472	38,617,580	125.15%
2025-09-30	46,596,484	37,794,088	123.29%
2025-06-30	38,936,319	35,822,308	108.69%
2025-03-31	35,287,915	35,790,700	98.60%
2024-12-31	35,041,048	33,313,849	105.18%
2024-09-30	31,281,193	34,236,728	91.37%
2024-06-30	29,664,353	34,227,038	86.67%
2024-03-31	25,872,116	25,665,475	100.81%
2023-12-31	10,209,178	5,153,423	198.10%
2023-09-30	10,000,368	3,906,886	255.97%
2023-06-30	27,325,987	874,900	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Dianthus Therapeutics, Inc. /DE/ (DNTH) — SEC Financial Statements & Analysis

Dianthus Therapeutics, Inc. /DE/ (DNTH) is a pharmaceutical preparations company, incorporated in DE. Dianthus Therapeutics, Inc. /DE/ trades on Nasdaq as: DNTH. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Dianthus Therapeutics, Inc. /DE/ reported a -76.45% year-over-year revenue growth, a Debt-to-Equity ratio of 0.04x, a Price-to-Sales (P/S) ratio of 4778.41x (TTM), a Price-to-Book (P/B) ratio of 4.66x (TTM), at a market cap of $5.46B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -76.45%
Debt To Equity: 0.04x
P/S TTM: 4778.41x
P/B TTM: 4.66x
Market Cap: $5.46B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Dianthus Therapeutics, Inc. /DE/ in?

Dianthus Therapeutics, Inc. /DE/ (DNTH) operates in the Pharmaceutical Preparations industry.

What is DNTH's market cap?

Dianthus Therapeutics, Inc. /DE/ (DNTH) has a market capitalization of $5.46B as of 2026-06-30.

What exchange does DNTH trade on?

Dianthus Therapeutics, Inc. /DE/ (DNTH) trades on the Nasdaq.

Where is Dianthus Therapeutics, Inc. /DE/ incorporated?

Dianthus Therapeutics, Inc. /DE/ is incorporated in DE.